Rahul Banerjee, MD, FACP

This account is verified. Learn more

@RahulBanerjeeMD

Associate Professor @UWMedicine @fredhutch. Goals: improve patient experience in myeloma: ⬇️ dex, 🙅🏼‍♂️ 24-hr urines, et al.

COI: coi.asco.org/share/VU2-FHC3…

Seattle, WA ncbi.nlm.nih.gov/myncbi/rahul.b… Joined March 2009

4.1K Following 12K Followers 36K Posts

Latest posts 5

Pinned post

Rahul Banerjee, MD, FACP @RahulBanerjeeMD Sep 26, 2024

Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible!

Dex 40mg weekly in #MMsm induction:

1️⃣ Not practical even for trial-enrolled patients
2️⃣ Does not improve PFS vs ⬇️ dex

Twitter 🧵 once I’m back from #IMS24!

ashpublications.org/blood/article/…

Robert Z. Orlowski @Myeloma_Doc Sep 26, 2024

#Myeloma Paper of the Day: Cool paper from @RahulBanerjeeMD showing analysis of S0777 and S1211 @SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/39321347/. #mmsm

View quoted post on X

Rahul Banerjee, MD, FACP @RahulBanerjeeMD 4d

Another chapter in #downwithdex ! Great work by @MMKingT #fridaaskeland et al on translating the SSQ-MM steroid-related PRO inventory into another language.

Turns out, regardless of what language you speak, dex-related AEs in myeloma are universal!

Ankit kansagra Verified account @kansagraMD 4d

Ask myeloma pts what they'd drop first from their regimen - we all know the answer !

Insomnia the night of, the crash two days later, mood changes families notice before the pt does, glucose all over the place. We dose-reduce it constantly and measure it with almost nothing.

Nice paper of the day from @Myeloma_Doc: the Steroid Symptom Questionnaire-MM (SSQ-MM, first validated in Australia) translated into Danish and Norwegian, with an initial psychometric look in newly diagnosed Norwegian pts on weekly dex (Rosenberg, Nielsen and colleagues, Qual Life Res).

Looking at paper there are three items
— Internal consistency acceptable: α 0.74 for the total score, 0.81 for the psychological subscale. Not suprising
— Scores rose during treatment and differed by ECOG PS, as they should. Fewer changes after dex was stopped, which I find interesting. Either symptoms linger, or the tool catches the rise better than the recovery
— Symptom levels ran lower than in the original Australian cohort. Culture, dosing, or who got enrolled? Can't tell from this

We are finally testing regimens that drop dex, like fixed-duration tec-pom with no dex in EAA242, or stopping dex early with dara-IRd. If dex-sparing is the claim, we need a validated way to show what pts actually gain. The QLQ-C30 isn't built for that.

But a steroid-specific PRO that works across langauges is exactly what multinational trials are missing. @HiraSMian @RahulBanerjeeMD this is something which echo's to our debate on steroids in bispecifics !

#Myeloma #PROs #mmsm
View quoted post on X

Rahul Banerjee, MD, FACP @RahulBanerjeeMD 4d

Infection PPx with bispecific antibodies in myeloma: is IVIG the answer?

…. Yes, but not so simple.

Come join @JoshuaRichterMD and me next Thursday (Nov 12th, 6pm ET = 3pm PT) as we share what we know and what we’ve seen!

Bactrim, vaccines, SCIG, and more. See you then!

Rahul Banerjee, MD, FACP @RahulBanerjeeMD Nov 3

What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma?

My best guess below... thanks @TheIACH @Mohty_EBMT for the invitation!

IACH Verified account @TheIACH Nov 3

🔴 We are Live!

CAR-T: Optimizing Bridging Therapy and Early Response

with Rahul Banerjee

Join the webinar →
t.co/U6QtyLzuuM

@RahulBanerjeeMD @Mohty_EBMT

View quoted post on X

Rahul Banerjee, MD, FACP @RahulBanerjeeMD Nov 3

Thanks @Mohty_EBMT for inviting me, and come join us!

Everything I've learned about bridging before CAR-T therapy in myeloma. Turns out we had the right idea all along, but partially for the wrong reasons...

Today's talk: nuts & bolts of bridging, and where field is headed...

IACH Verified account @TheIACH Nov 3

🔴 We are Live!

CAR-T: Optimizing Bridging Therapy and Early Response

with Rahul Banerjee

Join the webinar →
t.co/U6QtyLzuuM

@RahulBanerjeeMD @Mohty_EBMT

View quoted post on X